Skip Navigation


European Heart Journal Advance Access originally published online on March 21, 2005
European Heart Journal 2005 26(9):856-857; doi:10.1093/eurheartj/ehi215
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/9/856    most recent
ehi215v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stalenhoef, A. F.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stalenhoef, A. F.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Management of mixed hyperlipidaemia

Anton F.H. Stalenhoef*

Department of Internal Medicine, 541, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands

* Corresponding author. Tel: +31 243618819; fax: +31 243541734. E-mail address: a.stalenhoef@aig.umcn.nl

This editorial refers to ‘Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia’{dagger} by M. Farnier et al., on page 897

The first 10% of the full text of this article appears below.

The introduction of the HMG-CoA reductase inhibitors (statins) about 15 years ago has influenced the daily practice of cardiologists and other physicians enormously with respect to preventive strategies of first and second cardiovascular events. These drugs can lower the concentration of LDL-cholesterol by 30–60% and are generally well tolerated. In the last decade, randomized trials with statins have involved more than 90 000 patients, in which the overall safety and efficacy of the statins has been firmly established. The use of statins has, therefore, become the cornerstone of drug therapy in reducing the concentration of LDL-cholesterol and thereby the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
Michel Farnier, Mason W. Freeman, Geraldine Macdonell, Inna Perevozskaya, Michael J. Davies, Yale B. Mitchel, Barry Gumbiner, and for the Ezetimibe Study Group
EHJ 2005 26: 897-905. [Abstract] [FREE Full Text]